...
....
Pharmaceutical
Biotechnology

> See specialized channels
Medical Devices & Diagnostics
> See specialized channels
Industrial
Biotechnology
> See specialized channels


  Join us

  Follow us on Twitter   Join our LinkedIn Group   Our Blog

Biotech News App
Provides access to the latest biotech press releases ...more

Android_Logo App Store RIM_Logo_small

Media Partnership:
Want to have your RSS feed integrated on our website? Contact us
RSS Feeds RSS Feeds
JoomlaWatch Stats 1.2.9 by Matej Koval
For Editors
Sign up for press releases
For Companies
Sign up for our newsletter
Back to PRESS RELEASES - 

CEVEC Licenses its Proprietary Human Cell Lines to Paragon Bioservices, Inc.

| Print |
Thursday, 02 August 2012 11:00 (UTC + 2)

cevec_NEU_logo

 

Cologne, Germany, August 2, 2012 / B3C newswire /CEVEC Pharmaceuticals, the developer of a novel, market-leading human protein expression system derived from amniocytes, and Paragon Bioservices, Inc., a leading contract research and GMP manufacturing organization with a focus on the development and manufacturing of biopharmaceuticals, announced a joint collaboration earlier today—whereby Paragon Bioservices would license and use CEVEC’s know-how and patents (on CAP and CAP-T cell expression system) to develop stable cell lines and perform process development for the contract manufacturing of recombinant proteins and antibodies.  

“We are very pleased to be working with Paragon Bioservices,” said Wolfgang Kintzel, CEVEC’s CEO. “Since they provide preclinical research and development services and protein production for many of the large pharmaceutical companies, we believe that our collaboration will inevitably benefit the research community at-large.” 

Paragon’s CEO, Marco Chacón, PhD, agrees, “Even though our upstream developmental team has many years of experience in cell biology and bioprocess development, this is a highly competitive business.  Everyone needs an edge to meet the outsourcing challenges of our clients.  This valuable tool from CEVEC will assist us in offering clients a fully optimized human expression system that will express proteins with superior yields and in a shorter time frame than traditional methods. We look forward to a long relationship with CEVEC.”

 
About CEVEC Pharmaceuticals GmbH
CEVEC Pharmaceuticals GmbH, operational since 2004 and located in Cologne, Germany, is a biopharmaceutical company that specializes in developing and producing therapeutic proteins, vaccines and monoclonal antibodies with human glycosylation patterns. CEVEC’s novel proprietary and patent-protected human CAP® and CAP-T ™ expression systems are ideal for manufacturing complex biopharmaceutical molecules and various vaccines. CEVEC is licensing out its human cell-based expression platform as well as its own biobetter candidates through partnerships with renowned pharmaceutical and biotech companies.

About Paragon Bioservices, Inc.
Paragon is a Contract Research & GMP Manufacturing Organization (CMO) delivering research, development and manufacturing services. Paragon’s focus is biopharmaceuticals, including recombinant proteins, viral vectors, vaccines, VLPs, bacteriophage and stem cells. Our clients include pharmaceutical companies, biotechnology companies and federal agencies.


Contacts:

Wolfgang Kintzel
CEO
CEVEC Pharmaceuticals GmbH
Gottfried-Hagen Straße 62
D-51105 Köln, Germany
fon +49 (0) 221-46 02 08 – 00
fax +49 (0) 221-46 02 08 – 01
This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Marco A. Chacón, Ph.D.
President & CEO
Paragon Bioservices, Inc.
Baltimore, MD 21201
ph (410)975-4050 or
(410) 975-4052
This e-mail address is being protected from spambots. You need JavaScript enabled to view it or
This e-mail address is being protected from spambots. You need JavaScript enabled to view it